Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Lexeo Therapeutics Inc., 1 year.
Lexeo Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −106 | $319.03 | $33,817 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −102 | $320.01 | $32,641 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −215 | $320.81 | $68,974 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −289 | $321.82 | $93,006 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −350 | $323.01 | $113,054 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −767 | $323.84 | $248,385 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −272 | $324.88 | $88,367 |
| Mar 4, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −208 | $325.67 | $67,739 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Grant or award | +4,769 | — | — |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −47 | $323.62 | $15,210 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −90 | $324.65 | $29,219 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −258 | $325.63 | $84,013 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −392 | $326.81 | $128,110 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −329 | $327.67 | $107,803 |
| Mar 2, 2026 | Alnylam Pharmaceuticals Inc. | Open-market sale | −100 | $328.71 | $32,871 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.